Outlook Therapeutics IncOTLK
Price$0.57

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $1.4MTTM through 30 Jun 2026
Net Income -$61.1MTTM through 30 Jun 2026
Free Cash Flow -$56.2MTTM through 30 Jun 2026

Margins

Current
Operating Margin-47,320.3%
Net Margin-4,324.1%

Returns

210.2%ROE

Balance Sheet Health

Debt / Equity-0.94x
Current Ratio0.54x
Net Debt$19.4M
Cash & Equivalents$11.2M

Quality Metrics

Altman Z-Score-39.37
Piotroski F-Score3 / 9
FCF Margin-3,972.7%
Earnings-Beat Rate0.0%

Multi-Year Trend

Revenue
'25
FY2025: $1.4M
Diluted EPS-$0.70TTM
'18'20'21'22'23'24'25
FY2025: $-1.79

Dividend

No dividend
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.